spacer
home > epc > spring 2009 > oncology: biomarkers promise progress
PUBLICATIONS
European Pharmaceutical Contractor

Oncology: Biomarkers Promise Progress

The discovery and development of novel drugs remains a process fraught with high attrition rates and many technological, scientific and financial challenges. The cost to bring a new drug to market is estimated at $800 million and is predicted to increase 7.4 per cent above inflation on an annual basis (1). Over 75 per cent of these costs are expended on unsuccessful compounds and, in spite of billions spent on preclinical and clinical studies, post-launch withdrawal of compounds due to adverse side effects still occurs. Opportunities for the pharmaceutical industry lie in the integration of discovery and development functions to bring affordable, effective and safe drugs to patients. Many drug candidates still fail in clinical studies because we cannot accurately predict how effective or how safe these candidates will be in humans based solely on animal studies. Knowing the pharmacokinetics and pharmacodynamics of a drug candidate and the response of a patient to therapeutic intervention is crucial to successfully designing effective clinical trials. Biomarker technologies that are able to increase understanding of a drug’s mechanism of action at an early stage, precise dosing, and a regime of administration will generate valuable information on the drugs activity and accelerate the drug development process (2).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Lydia Meyer-Turkson is Director of the Biomarker Division at Epistem Ltd. She has a BSc honours and MPhil postgraduate degree in Chemistry from University College Cardiff and received an MBA from Manchester Business School. She has over 15 years business development experience in the contract research sector, setting up drug discovery and development collaborations between biotech and pharmaceutical companies across Europe and the US. She recently joined Epistem from a role as VP Business Development at Evotec AG.

spacer
Lydia Meyer-Turkson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Dynascan Discusses Company Advancements With Packaging Today Magazine

Dynascan’s Marketing Manager (MM) recently met up with Europe’s leading packaging magazine, Packaging Today. During the interview many topics were covered, and you can read the full article here, but below are a few highlights and brief summary of what was discussed…
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement